Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTL NASDAQ:EDSA NASDAQ:HOOK NASDAQ:RWOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$14.95-4.6%$9.16$4.92▼$28.60$8.57M1.34174,414 shs90,341 shsEDSAEdesa Biotech$2.40+1.3%$2.03$1.55▼$5.59$16.64M0.39493,663 shs19,699 shsHOOKHOOKIPA Pharma$1.14$1.38$0.72▼$6.68$13.90M0.8982,663 shs185,284 shsRWODRedwoods Acquisition$0.73$0.93$2.22▼$13.10$3.75MN/A108,185 shs22,784 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences-4.59%-37.40%+146.29%+161.24%+99.33%EDSAEdesa Biotech+1.27%+14.83%+17.65%+6.19%-48.83%HOOKHOOKIPA Pharma0.00%-4.20%-12.64%+47.42%-82.43%RWODRedwoods Acquisition0.00%0.00%0.00%0.00%-56.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTLArtelo Biosciences2.1328 of 5 stars3.83.00.00.01.10.00.6EDSAEdesa Biotech1.4693 of 5 stars2.05.00.00.00.61.70.6HOOKHOOKIPA Pharma2.897 of 5 stars3.25.00.00.01.81.70.6RWODRedwoods AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 3.60Strong Buy$25.0067.22% UpsideEDSAEdesa Biotech 4.00Strong Buy$5.00108.33% UpsideHOOKHOOKIPA Pharma 2.33Hold$4.50294.74% UpsideRWODRedwoods Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RWOD, EDSA, HOOK, and ARTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/8/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$20.006/27/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$5.006/11/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/6/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.004/28/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A$5.31 per shareN/AEDSAEdesa BiotechN/AN/AN/AN/A$0.61 per shareN/AHOOKHOOKIPA Pharma$43.95M0.32N/AN/A$4.25 per share0.27RWODRedwoods AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$9.83M-$17.94N/AN/AN/AN/A-226.99%-164.61%8/12/2025 (Estimated)EDSAEdesa Biotech-$6.17M-$1.59N/AN/AN/AN/A-187.01%-78.72%8/8/2025 (Estimated)HOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%8/6/2025 (Estimated)RWODRedwoods AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ALatest RWOD, EDSA, HOOK, and ARTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025HOOKHOOKIPA Pharma-$0.64N/AN/AN/AN/AN/A8/12/2025Q2 2025ARTLArtelo Biosciences-$0.13N/AN/AN/AN/AN/A8/8/2025N/AEDSAEdesa Biotech-$0.23N/AN/AN/AN/AN/A5/15/2025Q1 2025HOOKHOOKIPA Pharma-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A5/14/2025Q2 2025EDSAEdesa Biotech-$0.30-$0.30N/A-$0.30N/AN/A5/13/2025Q1 2025ARTLArtelo Biosciences-$0.78-$4.32-$3.54-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/ARWODRedwoods AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A0.490.49EDSAEdesa BiotechN/A15.7215.72HOOKHOOKIPA PharmaN/A3.613.61RWODRedwoods AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%EDSAEdesa Biotech5.50%HOOKHOOKIPA Pharma63.88%RWODRedwoods Acquisition20.07%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences0.83%EDSAEdesa Biotech22.60%HOOKHOOKIPA Pharma3.30%RWODRedwoods Acquisition2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences5550,000542,000Not OptionableEDSAEdesa Biotech207.02 million5.44 millionNot OptionableHOOKHOOKIPA Pharma16012.19 million11.79 millionOptionableRWODRedwoods AcquisitionN/A5.17 million5.06 millionNot OptionableRWOD, EDSA, HOOK, and ARTL HeadlinesRecent News About These CompaniesGM teams up with Redwood Materials to power data centers with EV batteriesJuly 16 at 6:36 PM | msn.comCal Redwood Acquisition Corp. Announces Pricing of $200 Million Initial Public OfferingMay 23, 2025 | bakersfield.comBRedwood Holdings Limited vow to return Reading ‘to its rightful place in English football’ after completing takeoverMay 15, 2025 | nytimes.comRedwood Services Makes 19th AcquisitionMay 15, 2025 | achrnews.comARedwood Announces Investment by Atlas PartnersMay 9, 2025 | achrnews.comARedwood Materials preps for expansion spree with new R&D center in San FranciscoApril 2, 2025 | msn.comBlank-Check Company Cal Redwood Files for IPOMarch 4, 2025 | marketwatch.comEnvironmental Groups Praise Plan to Conserve Coastal Redwoods, Expand Protected LandFebruary 20, 2025 | sanjoseinside.comS$24 million land deal creates 7-mile-long Bay Area corridor of protected redwood forests to the oceanFebruary 12, 2025 | msn.comSave the Redwoods League signs $24 million deal to purchase Monte Rio redwood forest and expand county parkFebruary 12, 2025 | pressdemocrat.comP$24 million land deal creates 7-mile long corridor of protected redwood forests to the oceanFebruary 11, 2025 | eastbaytimes.comERedwood Gospel Mission finalizes purchase of former SAY Dream Center in Santa RosaJanuary 5, 2025 | pressdemocrat.comPRedwood Empire Whiskey Acquires Luxury Northern California DistilleryDecember 21, 2024 | markets.businessinsider.comAcacia Capital buys Redwood City apartments for $184MNovember 13, 2024 | therealdeal.comTRedwood Realty Negotiates $6.6M Sale of Jersey City Apartment BuildingOctober 24, 2024 | rebusinessonline.comRSave the Redwoods League acquires 750 acres of Redwood Forest in Sonoma and Mendocino Counties for future parks expansionsOctober 13, 2024 | ukiahdailyjournal.comUOne of California's most popular old-growth redwood parks is about to get biggerOctober 11, 2024 | msn.comSave the Redwood League acquires 750 acres of land to expand Montgomery Woods, Armstrong WoodsOctober 11, 2024 | mendovoice.comMRedwood Gospel Mission in line to buy former SAY Dream Center campus in Santa RosaOctober 6, 2024 | pressdemocrat.comPBMW of North America partners with Redwood MaterialsSeptember 27, 2024 | recyclingtoday.comRNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRWOD, EDSA, HOOK, and ARTL Company DescriptionsArtelo Biosciences NASDAQ:ARTL$14.95 -0.72 (-4.59%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$14.47 -0.48 (-3.18%) As of 07/18/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Edesa Biotech NASDAQ:EDSA$2.40 +0.03 (+1.27%) Closing price 07/18/2025 03:55 PM EasternExtended Trading$2.40 +0.00 (+0.21%) As of 07/18/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.HOOKIPA Pharma NASDAQ:HOOK$1.14 0.00 (0.00%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.18 +0.04 (+3.51%) As of 07/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Redwoods Acquisition NASDAQ:RWODRedwoods Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. In intends to focus on businesses in the carbon neutral and energy storage industries. The company was incorporated in 2021 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
